Pegaptanib

Pegaptanib, a groundbreaking medical substance, belongs to a class of drugs known as VEGF inhibitors. Specifically, it is an aptamer, a type of single-stranded RNA molecule that selectively binds to and neutralizes vascular endothelial growth factor (VEGF). VEGF plays a crucial role in the formation of new blood vessels, a process called angiogenesis, which is essential for the growth and survival of tumors.
Pegaptanib is primarily used for the treatment of a specific type of age-related macular degeneration (AMD), known as neovascular (wet) AMD. Wet AMD is characterized by the growth of abnormal blood vessels under the retina, which can lead to severe vision loss if left untreated. Pegaptanib works by inhibiting VEGF, thereby preventing the growth of these new blood vessels and slowing down the progression of the disease.
In clinical trials, pegaptanib has demonstrated its efficacy in preserving vision and improving the overall quality of life for patients with wet AMD. It is typically administered as an intravitreal injection, delivered directly into the eye by a healthcare professional, ensuring that the medication reaches the targeted area with minimal systemic side effects.